Tesamorelin Side Effects: What the Egrifta Label Actually Says

The most common side effects of tesamorelin on its label are injection-site reactions, joint pain, pain in the arms and legs, muscle aches and swelling, each more frequent than on placebo. The more serious warnings concern blood sugar, persistently high IGF-1, fluid retention, allergic reactions and cancer risk. All of it comes from trials in adults with HIV and excess abdominal fat, which is the only use tesamorelin is approved for.

Who the label's safety data describes

Tesamorelin is sold as Egrifta WR and Egrifta SV. It is a growth hormone-releasing factor analog, approved for one thing: reducing excess abdominal fat in HIV-infected adults with lipodystrophy¹. The label cited here is the Egrifta WR prescribing information on DailyMed, revised March 2025, in the version published in August 2026.

Every side-effect rate on that label comes from the same group of people:

• 740 adults with HIV and excess abdominal fat were treated in the clinical trials, and 543 of them received tesamorelin during the 26-week placebo-controlled phase¹.
• They were 18 to 65 years old, on stable HIV treatment, with a large waist¹.
• People with type 1 or type 2 diabetes, anyone on insulin or diabetes pills, anyone with a history of cancer, and anyone with a body mass index of 20 or below were excluded¹.

That matters when you read the numbers. A healthy 40-year-old using tesamorelin for belly fat, or someone with prediabetes, is outside the population these rates describe. The Egrifta WR label also notes that its safety rests on trials of the older 1 mg-per-vial formulation, and that side effects of the current dose are expected to be similar¹.

The adverse reactions, by how often they happened

The label's Table 1 lists reactions that occurred in at least 1% of treated patients and more often than on placebo during the first 26 weeks. These are the most frequent.

Two things stand out. Joint pain was common on placebo too, at 11%, so tesamorelin adds only a few percentage points to it. Injection-site reactions nearly tripled. Counting every kind of injection-site reaction, including redness, itching, pain, irritation and bruising, the label puts it at 25% on tesamorelin against 14% on placebo¹.

Swelling, joint pain, tingling and carpal tunnel syndrome belong together. The label attributes them to fluid retention caused by the rise in growth hormone, and says they are either temporary or resolve when treatment stops¹.

The warnings that matter more than the table

The adverse-reaction table covers what is common. The warnings cover what is serious. Tesamorelin's label carries six¹:

• Blood sugar. In the trials, 5% of people on tesamorelin developed an HbA1c of 6.5% or higher, the diabetes threshold, against 1% on placebo. The label gives a hazard ratio of 3.3 and tells prescribers to check glucose before and during treatment.
• High IGF-1. Among people on tesamorelin for 26 weeks, 47% had IGF-1 more than two standard deviations above normal, and 36% more than three. The label states that the effects of prolonged high IGF-1 are unknown.
• Cancer. Because tesamorelin raises growth hormone, it must not be used by anyone with an active cancer, and should be stopped if a cancer recurs.
• Fluid retention, as described above.
• Allergic reactions in 4% of treated patients, including itching, redness, flushing, hives and rash.
• Acute critical illness. Growth hormone given in large doses has been linked to higher death rates after major surgery or trauma, so the label advises considering stopping tesamorelin in critically ill patients.

It is also contraindicated in pregnancy, in people with a damaged pituitary axis, and in anyone allergic to it¹.

One more finding sits in the label's pharmacology section rather than its warnings. Antibodies against tesamorelin developed in 50% of people treated for 26 weeks, and in 85% of those who had an allergic reaction. The label reports that people with and without these antibodies had similar reductions in visceral fat¹.

The trial before and after: visceral fat at 26 weeks

Tesamorelin's "before and after" is a CT scan, not a photograph. The trials measured visceral fat, the fat packed around the organs, at one level of the lower spine.

The pattern is specific. Visceral fat fell by about a sixth. Weight did not move. The label reports trunk fat down 0.8 to 1.0 kg and lean body mass up 1.2 to 1.3 kg in the treated groups¹. That is why the label calls the drug "weight neutral": fat moved out of one compartment, but the scale did not change.

The result also does not last on its own. In the extension phase, people who had taken tesamorelin for 26 weeks were switched to placebo. Their visceral fat rose again by 22% in Study 1 and 16% in Study 2 over the next 26 weeks¹. A 2026 meta-analysis of five randomized trials confirmed the visceral-fat, trunk-fat and liver-fat reductions, and found no significant change in body mass index or in the fat under the skin⁶.

Why compounded tesamorelin has no lawful route

Tesamorelin is regulated as a biologic. On March 23, 2020, FDA converted a set of approved drug applications for biological products into biologics licenses, and its published list of them includes "tesamorelin acetate, Egrifta and Egrifta SV," application 022505².

That change closes the door on compounding. Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act are what allow pharmacies and outsourcing facilities to compound. FDA's guidance on biological products states that, for those sections, a drug does not include a biologic licensed under the Public Health Service Act, and that "the FD&C Act does not provide a legal pathway for marketing biological products that have been prepared outside the scope of an approved BLA"³.

So there is no lawful compounded tesamorelin. A product sold as compounded tesamorelin is not the drug on the label above, and the side-effect rates on that label do not describe it. Our explainer on why compounded is not the trial drug covers the general version of this problem, and the tesamorelin and ipamorelin blend page covers one common way it is sold.

Off-label belly-fat use

Tesamorelin is marketed well beyond HIV for stubborn belly fat. One randomized trial has tested that idea directly. Sixty adults with abdominal obesity and reduced growth hormone secretion, none of them with HIV, took tesamorelin or placebo for 12 months. Visceral fat fell compared with placebo, triglycerides and C-reactive protein improved, and there were no serious adverse events and no difference in adverse events between the groups. Blood sugar and HbA1c did not change⁷.

That is an encouraging single trial. It is not an approval. The label is explicit that tesamorelin "is not indicated for weight loss management as it has a weight neutral effect," and that its long-term cardiovascular safety has not been established¹. The trial enrolled people selected for low growth hormone secretion, and its results do not extend to anyone who simply wants a flatter stomach.

For the full evidence record, see our tesamorelin page. The visceral fat guide compares what else has been tested for that goal, and the sermorelin vs. tesamorelin comparison sets the two GHRH analogs side by side. What sermorelin's own studies measured is on our sermorelin before-and-after page.